A Phase 2 Study to Evaluate the Safety and Efficacy of Intravenously Administered Benralizumab (MEDI-563).

Exclusion Criteria

• •Known history of allergy or reaction to any component of the investigational product formulation
• •Acute illness other than asthma at the start of the study
• •Fever more than (\>) 38.6 degrees Celsius (C) (\>101.5 degrees Fahrenheit \[F\])
• •Current acute asthma attack is due to aspirin-induced asthma
• •Current asthma episode is an anaphylactoid/anaphylactic reaction presenting with acute bronchospasm
• •Evidence of clinically significant non-respiratory active infection, including ongoing chronic infection
• •History or current prolonged diarrhea, abdominal pain, and/or blood and mucus in stools or have minor symptoms and have exposure to stream or lake water, been exposed to someone who has a parasitic infection (like a family member), or study subject has traveled outside the United States of America (USA) and/or Canada within the last year
• •Use of immunosuppressive medication (except oral prednisone and inhaled and topical corticosteroids) within 30 days before randomization into the study
• •Have received Xolair within 6 months before randomization into the study
• •Receipt of immunoglobulin or blood products within 30 days before randomization into the study
• •Receipt of any investigational drug therapy within 6 months before the first dose of investigational product in this study through Day 168
• •History of primary immunodeficiency
• •Previous medical history, or evidence, of an intercurrent illness that may compromise the safety of the subject in the study
• •History of clinically significant abnormality on ECG in the opinion of the investigator
• •Pregnancy (must have a negative serum pregnancy test prior to the first dose of investigational product)
• •Breastfeeding or lactating woman
• •History of treatment for alcohol or drug abuse within the past year
• •Diagnosis of chronic obstructive pulmonary disease (COPD) by a healthcare professional
• •Evidence of any clinically significant systemic disease on physical examination
• •History of cancer except basal cell carcinoma or in situ carcinoma of the cervix treated with apparent success with curative therapy \>1 year prior to entry or other malignancies treated with apparent success with curative therapy \>5 years prior to entry
• •Known exposure to inhaled occupational agents or fumes with an established diagnosis of occupational asthma
• •Any condition (that is, impending ventilatory failure or hemodynamic compromise) that, in the opinion of the investigator, would interfere with evaluation of the investigational product or interpretation of study results
• •Any employee of the clinical study site who is involved with the conduct of the study
• •History of cigarette smoking \>20 pack years
• •Previously received benralizumab (MEDI-563)
• •Asthma exacerbation due to acute inhalational exposure.